KBC Group
ADVM

KBC Group’s Adverum Biotechnologies ADVM Stock Holding History

KBC Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-210
Closed -$7K – 1290
2021
Q2 		$7K Hold
210
– – ﹤0.01% 1268
2021
Q1 		$21K Buy
210
+200
+2,000% +$24K ﹤0.01% 1276
2020
Q4 		$1K Hold
10
– – ﹤0.01% 1258
2020
Q3 		$1K Hold
10
– – ﹤0.01% 1221
2020
Q2 		$2K Hold
10
– – ﹤0.01% 1263
2020
Q1 		$1K Hold
10
– – ﹤0.01% 1272
2019
Q4 		$1K Sell
10
-11
-52% -$970 ﹤0.01% 1489
2019
Q3 		$1K Sell
21
-199
-90% -$22.4K ﹤0.01% 1474
2019
Q2 		$26K Hold
220
– – ﹤0.01% 1400
2019
Q1 		$12K Hold
220
– – ﹤0.01% 1389
2018
Q4 		$7K Hold
220
– – ﹤0.01% 1296
2018
Q3 		$13K Hold
220
– – ﹤0.01% 1380
2018
Q2 		$12K Hold
220
– – ﹤0.01% 1275
2018
Q1 		$13K Buy
+220
New +$13.7K ﹤0.01% 1258

Other funds holding ADVM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KBC Group's ADVM Position: Q3 2021 in Review

KBC Group sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 210 shares — an estimated $7K sold.

KBC Group first reported a position in ADVM in Q1 2018 and held it in 14 quarters. The position peaked at $26K in Q2 2019. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • KBC Group reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • KBC Group sold 210 Adverum Biotechnologies shares in Q3 2021, an estimated $7K.
  • KBC Group first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 14 quarters.
  • KBC Group's Adverum Biotechnologies position peaked at $26K in Q2 2019.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on KBC Group's 13F filing for Q3 2021, filed 10 Nov 2021.